Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Faron Pharmaceuticals Oy ( (GB:FARN) ).
Faron Pharmaceuticals announced updated data from its Phase I/II BEXMAB study, highlighting significant clinical activity of bexmarilimab in treating higher-risk myelodysplastic syndrome (HR-MDS). The study, presented at the ESMO 2025, showed an 85% objective response rate and a 45% complete remission rate in treatment-naïve patients, with new biomarker data revealing a strong correlation between target engagement and clinical response. These findings reinforce bexmarilimab’s potential as a disease-modifying agent, differentiating it from other therapies and paving the way for further clinical development.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel immunotherapies to tackle cancers. The company is known for its innovative approach in targeting the Clever-1 receptor to enhance anti-tumor immunity.
For an in-depth examination of FARN stock, go to TipRanks’ Overview page.